share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K:重大事件
美股SEC公告 ·  06/03 17:27

Moomoo AI 已提取核心信息

Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration...Show More
Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration statement with the SEC. In conjunction with the Spin-Off, Illumina anticipates incurring charges between $35 and $50 million, mainly for legal and advisory fees, with the majority expected in Q2 and the remainder by Q3 of 2024. Additionally, the Spin-Off may lead to a potential goodwill impairment for Illumina, which could be recognized following an interim test in Q2 of 2024. The company's balance sheet as of March 31, 2024, shows $1,466 million in goodwill, $561 million in non-amortizing in-process research and development, and $2,092 million in net amortizing intangible assets related to GRAIL.
生物技术公司illumina宣布其子公司GRAIL的Spin-Off获得公司董事会批准。这项Spin-Off将导致至少85.5%的GRAIL普通股以比例红利形式分配给Illumina的股东。该分配计划于2024年6月24日纽约市时间上午12:01生效,预计GRAIL将在随后的一天以GRAL为股票代码在纳斯达克全球精选市场上交易。截至股权登记日期2024年6月13日,Illumina的股东每持有6股Illumina股票将获得1股GRAIL股票。Spin-Off取决于GRAIL在SEC提交的10号表格中所概述的某些条件。在Spin-Off方面,Illumina预计将承担3500万至5000万美元的...展开全部
生物技术公司illumina宣布其子公司GRAIL的Spin-Off获得公司董事会批准。这项Spin-Off将导致至少85.5%的GRAIL普通股以比例红利形式分配给Illumina的股东。该分配计划于2024年6月24日纽约市时间上午12:01生效,预计GRAIL将在随后的一天以GRAL为股票代码在纳斯达克全球精选市场上交易。截至股权登记日期2024年6月13日,Illumina的股东每持有6股Illumina股票将获得1股GRAIL股票。Spin-Off取决于GRAIL在SEC提交的10号表格中所概述的某些条件。在Spin-Off方面,Illumina预计将承担3500万至5000万美元的费用,主要是法律和咨询费用,大部分在2024年Q2期间出现,剩余部分在Q3期间出现。此外,Spin-Off可能导致Illumina的潜在商誉减值,该减值可能在2024年Q2的中期测试后被确认。截至2024年3月31日,该公司的资产负债表显示了14.66亿美元的商誉,5.61亿美元的未摊销进程研究和开发费用,以及20.92亿美元的与GRAIL相关的净摊销无形资产。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息